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Abstract 
The choice of injected dose of 
18
F -FDG and acquisition time is important in obtaining 
consistently high-quality PET images. The aim of this study was to determine the 
optimal acquisition protocols based on patient weight for 3-dimensional lutetium 
oxyorthosilicate PET/CT. Methods: This study was a retrospective analysis of 76 
patients ranging from 29 to101 kg who were injected with 228–395.2 MBq of 
18
F -FDG 
for PET imaging. The study population was divided into 4 weight-based groups: less 
than 45 kg (group 1), 45–59 kg (group 2), 60–74 kg (group 3), and 75 kg or more 
(group 4). We measured the true coincidence rate, random coincidence rate, 
noise-equivalent counting rate (NECR), and random fraction and evaluated image 
quality by the coefficient of variance (COV) in the largest liver slices. Results: The true 
coincidence rate, random coincidence rate, and NECR significantly increased with 
increasing injected dose per kilogram (r = 0.91, 0.83, and 0.90; all P < 0.01).  NECR 
maximized at10.11 MB/kg in underweight patients. The true coincidence rate differed 
significantly among the 4 groups, except for group 3 versus group 4 (P < 0.01). The 
ratio of the true coincidence rate for group 2 to groups 3 and 4 was 1.4 and 1.6, 
respectively.  The average random fraction for all 4 groups was approximately 35%.  
The COV of the 4 groups differed for all pairs (P< 0.01). The COVs in overweight 
patients were larger than those in underweight patients, and image quality in overweight 
patients was poor. Conclusion: We modified acquisition protocols for 
18
F -FDG PET/CT 
according to the characteristics of a 3-dimensional lutetium orthosilicate PET scanner 
and PET image quality based on patient weight. The optimal acquisition time was 
approximately 1.4–1.6 times longer in over-weight patients than in normal-weight 
patients. Estimation of optimal acquisition times using the true coincidence rate is more 
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Whole-body PET using 
18
F -FDG is a valuable molecular imaging modality in the 
clinical management of patients with cancer (1). The synthesis of 
18
F -FDG requires an 








F -FDG is also now available from commercial suppliers in most 
regions of Japan. However, when 
18
F -FDG is purchased commercially, it is difficult to 
increase or decrease the injected dose according to the weight of the patients, and the 
radioactivity for 
18
F -FDG administration is a constant quantity. In underweight patients 
therefore, the result is an increase in the relative radiation dose, whereas in overweight 
patients there is an increase in statistical noise because of the low relative injected dose, 
and PET image quality may be poor (2–4). Therefore, associating the injected dose of 
18
F -FDG per kilogram of patient weight with the best acquisition time is important in 
obtaining high-quality PET images. The standard injected dose of 
18
F-FDG using a PET 
scanner with bismuth germinate crystals is 2.0–5.0 MBq/kg according to the guidelines 
of the Japanese Society of Nuclear Medicine. However, the administered activity of the 
radiopharmaceutical may vary for other systems and acquisition protocols (5). 
In current PET/CT systems, the high light output and fast decay time of lutetium 
oxyorthosilicate (LSO) detectors, compared with bismuth germinate detectors, reduce 
system dead time and improve counting rate  performance, resulting in particularly 
high activity levels in the field of view (6,7). These features allow whole-body scans to 
be acquired in 3-dimensional (3D) mode rather than 2-dimensional mode, thereby 
greatly enhancing the sensitivity of the PET scanner (7). However, true and random 
counting rates and noise-equivalent counting rate (NECR), which affect PET image 
quality, are not universal functions for specific scanners, injected doses of 
18
F -FDG, or 
patient weights (8). Furthermore, high photon attenuation and scatter in obese patients 
affect image quality. Thus, the aim of this study was to optimize 3D LSO 
18
F -FDG 
PET/CT acquisition protocols for patient weight by measuring true counting rate, 
random counting rate, and NECR in clinical scanning. 
 
MATERIALS AND METHODS 
Study Population 
This was a retrospective analysis of 76 patients (mean age, 63.3 ± 11.6 y) who 
underwent clinical 
18
F -FDG PET/CT. The patients were evaluated for lung cancer (n = 
15), malignant lymphoma (n = 14), cancer screening (n = 13), head and neck cancer (n 
= 10), breast cancer (n = 8), colorectal cancer (n = 7), esophageal cancer (n = 2), 
pancreatic cancer (n = 2), ovarian cancer (n = 2), an unknown primary tumor (n = 2), 
and thyroid cancer (n = 1). The patients for this study were selected from our 
18
F -FDG 
PET/CT database. Patients with liver metastases or with hyperglycemia at the time of 
18
F -FDG injection were excluded. The patients had an average weight of 55.6 ±17.5 
kg (range, 29–101 kg), and their height averaged 158.4 ± 9.4cm (range, 135.7–177.5 
cm).  The study population was divided into 4 groups based on weight: group 1, less 
than 45 kg (average, 38.6 ± 4.1 kg, n =27); group 2, 45–59 kg(average, 52.1 ± 4.6 kg,  
n = 22); group 3, 60–74 kg (average, 67.5±5.2 kg, n = 15); and group 4, 75 kg or more 
(average, 85.± 6 7.8 kg, n = 12).  
This study was performed with the approval of the institutional review board, and 
written informed consent was obtained from all patients before PET/CT examination.  
 
Image Acquisition  
Images ware obtained with an LSO PET/CT scanner that combines a 16-multislice 
CT scanner (Aquiduo PCA-7000B; Toshiba Medical Systems) with a high-resolution 
PET scanner (HI-REZ system; CPS Innovations) coupled to PICO-3D detector 
electronics (CPS Innovations) (9). The PET images were acquired in 3D mode only. All 
patients fasted at least 4 h before undergoing PET/CT. After their blood sugar had been 
checked (average, 103.4 ± 12.9 mg/dL), patients received an intravenous injection of 
18
F 
-FDG (FDGSCAN; Nihon Medi-Physics) using an automatic injector (UG-01; 
Universal Giken) and then rested quietly in bed for approximately 60 min. The injected 
activity of 
18
F -FDG ranged from 228 to 395.2 MBq (average, 339.0 ± 38.7 MBq). The 
injected doses of 
18
F -FDG per kilogram of patient weight were as follows: group 1, 9.0 
± 1.7 MBq/kg; group 2, 6.6 ± 1.0 MBq/kg; group 3, 4.8 ± 0.7 MBq/kg; and group 4, 4.0 
± 0.5 MBq/kg.  
All patients were placed supine, with the arms down, on the imaging table. PET/CT 
examinations began with the acquisition of a scout scan. After the coaxial imaging 
range had been defined as being from the skull to the mid thigh, diagnostic-quality CT 
images were obtained using the following parameters: 120 kVp, automatic exposure 
control depending on body habitus, 0.5-s rotation, 2-mm slice thickness, and a table 
feed of 30 mm per rotation. CT was performed during expiratory breath-hold to 
minimize attenuation artifacts, and high-quality lung images were obtained. We used an 
automatic exposure control in CT with tube current modulation to achieve a constant 
level of image quality that used the SD of the CT number. After the CT scan, PET 
images were acquired for 120 s per bed position. Eighty-one slices with a slice thickness 
of 2 mm were obtained for each bed position. PET images were acquired at multiple bed 
positions over the same range as for the CT scan during shallow breathing. PET images 
were reconstructed into a 128×128 matrix with 1.34 zooming, using interactive  
algorithms (ordered-subset expectation maximization, 4 iterations, 14 subsets) and the 
CT-based attenuation correction, and noise was reduced by smoothing the images with a 
gaussian filter of 8 mm in full width at half maximum. 
 
Data Analysis 
The prompt and random coincidence rates were obtained as the sinogram data of the 
bed position that covered the liver in the whole-body scan. The measure used to 
evaluate the performance of the PET scanner was T = P – S – R, where T is the true 
coincidence rate, P is the prompt coincidence rate, S is the scattered coincidence rate, 
and R is the random coincidence rate. The optimized injected dose per kilogram was 
estimated as NECR by T
2 
/ (T + S + kR), where k = 2 (noise random correction factor). 
Because the prompt and random data were selected from sinogram data, we chose to 




Quantitative analysis of image quality was performed using the coefficient of 
variance (COV) in the region of interest (ROI), defined as a circular region 15.2 cm
2
 in 
diameter over the largest liver section on transverse PET slices. The ROI was placed 
and measured by an experienced, certified nuclear medicine technologist. In general, 
PET image quality was evaluated for smoothness of the liver. Percentage COV was 
calculated as the SD of the ROI counts divided by the mean count of the ROI, 
multiplied by 100.  
 
Statistical Analysis  
The relationships between injected dose per kilogram, T, S, and random fraction were 
evaluated by linear regression analysis and Pearson product-moment correlation 
coefficient. Multiple comparisons of the 4 groups for T and COV were performed by the 




Clinical Characteristics of PET Scanner 
The true coincidence rate and random coincidence rate increased significantly with 
increasing injected dose per kilogram (r = 0.91, P < 0.01, and r = 0.83, P < 0.01, 
respectively; Figs. 1A and 1B). NECR increased significantly with increasing injected 
dose per kilogram (r = 0.90, P < 0.01), but NECR achieved its maximum of 95.69 cps at 
10.11 MBq/kg, and increasing the dose did not affect NECR (Fig. 1C).  
 
Relationship Between True Coincidence Rate and Image Quality 
An increase in the injected dose per kilogram was associated with an improvement in 
image quality. At lower injected doses, the COV of PET images showed a steep decline. 
Higher COVs of 10% or more were observed at injected doses lower than 4–5 MBq/kg 
(Fig. 2). Figure 3 illustrates a representative scan for each weight group.  
The true coincidence rate decreased with increasing patient weight: group 1 had an 
average of 177.80 ± 30.60 cps; group 2, 142.28 ± 19.85 cps; group 3, 103.74 ± 17.25 
cps; and group 4, 90.78 ± 13.67 cps (Fig. 4A). The true coincidence rates of the 4 
groups were significantly different from each other except for group 3 versus group 4. 
The ratios of the true coincidence rate for group 2 to groups 1, 3, and 4 were 0.8, 1.4, 
and 1.6, respectively. The COV of PET images increased with increasing patient weight: 
group 1 had an average of 5.64% ± 1.02%; group 2, 7.52% ± 2.18%; group 3, 10.98% ± 
2.54%; and group 4, 14.15% ± 2.35% (Fig. 4B). Higher COVs were observed in group 
4. Significant differences were 
observed for all pairs of each 
group (P < 0.01). The random 
fraction showed no significant 
differences for any pairs of each 
group, and the average random 
fraction for all 4 groups was 
approximately 35% (Fig. 4C). 
 
DISCUSSION 
We found that an injected dose of more than approximately 10 MBq/kg did not 
contribute to greater image quality in thin patients for a peak NECR, and PET image 
quality declined for a lower true coincidence rate in over-weight patients of 75 kg or 
more. However, because random fraction was independent of patient weight, these 
findings suggested that the same image quality could be obtained with a longer 
acquisition time.  
With the development of PET/CT, 
18
F -FDG PET has been more widely used in the 
diagnosis and staging of malignant disease. In addition, 
18
F -FDG is also now available 







Ga. However, it is difficult to regulate the injected dose 
according to the weight of individual patients. If the injected dose in an overweight 
patient cannot produce high-quality PET images, the PET acquisition time is prolonged 
on the basis of empiric observation (2, 5, 10). Obesity affects PET image quality 
because of high photon attenuation and scatter. Therefore, we attempted to make 
adjustments to the acquisition protocols based on patient weight to optimize 
18
F -FDG 
PET/CT image quality. The quality of PET images in obese patients is degraded. The 
true and random coincidence rates increase significantly with increasing injected dose 
per kilogram, and the average random fraction was approximately 35% in this study. 
The true coincidence rate is proportional to the activity present, and the random 
coincidence rate is proportional to the square of the activity present. Therefore, random 
fraction increases linearly with activity (6). In this study, the true coincidence rate 
decreased with increasing patient weight at almost a fixed injected dose. The injected 
dose per kilogram in overweight patients was low, and the random coincidence rate was 
decreased. Because random fraction, which influences PET image quality, is unrelated 
to patient weight, PET image quality may be determined by the acquisition time (Fig. 5). 
 
A higher injected dose significantly increased NECR, and the NECR curve peaked at 
10.11 MBq/kg. This curve represents the exposure dose increase to a greater extent than 
does a higher injected dose in underweight patients, and PET quality is not improved by 
injected dose. The peak NECR attained in the phantom is different from phantom size 
and higher than mean patient value. Local experiments with a 70-cm NEMA phantom 
indicated that NECR with Acquiduo PCA-7000B (Toshiba Medical Systems) showed 
saturation for activities exceeding 12 MBq/kg. Therefore, the maximum injected dose in 
underweight patients is less than approximately 10 MBq/kg in 3D LSO PET/CT.  
The COV of PET images was significantly higher for a low dose per kilogram, that is, 
higher in overweight patients than in underweight patients. In fact, patients over 75 kg 
showed a decrease in megabecquerels per kilogram, and the COV of PET images 
increased from 5.65 to 14.15. With the same injected dose, PET image quality was 
better in underweight patients than in overweight patients. Both the total true counts and 
the visual score of PET images had significant negative correlations with weight (11). 
However, the injected dose of 
18
F -FDG from commercial suppliers is not an adequate 
activity for overweight patients. Therefore, alternative protocols with longer acquisition 
times should be adopted to compensate for the loss of image quality (10). Because the 
random fractions remained steady, PET was evaluated with the same image quality for 
longer acquisition times. Acquisition times were estimated according to the relationship 
found between the true coincidence rate and the weight ranges of the 4 groups. The ratio 
of the true coincidence rate for group 2 to groups 3 and 4 were 1.4 and 1.6, respectively, 
and the estimated acquisition times for groups 3 and 4 were 170 and 190 s, respectively, 
per bed position.  
PET image quality was evaluated for the COV in an ROI over the liver. The liver has 
often been used to distinguish image quality because it shows relatively high-level 
accumulation of 
18
F -FDG under physiologic conditions (4, 11). In overweight patients, 
the COVs were larger than those in underweight patient and images were noisy. This 
study was performed to determine the best acquisition protocol for 3D LSO 
18
F -FDG 
PET/CT, and the findings suggested that the maximum injected dose was approximately 
10 MBq/kg in underweight patients. The optimal acquisition time was approximately 
1.6 times longer in overweight patients than in patients of normal weight.  
In 
18
F -FDG PET scans, injected dose is one factor determining image quality. 
However, the radiation dose in the patient from radiopharmaceuticals should be kept as 
low as possible, particularly for younger patients. In this study, patients received an 
average injected dose of 340 MBq of 
18
F -FDG. Because the ratio of the true 
coincidence rate for group 2 to group 1 was 0.8, the injected dose in underweight 
patients was estimated to be 270 MBq. If the COV is accepted to be 10%, the injected 
dose should be kept under 200MBq in adolescent patients because the ratio of the true 
coincidence rate for group 3 to group 1 was 0.6. 
This study had several limitations. First, the clinical prompt and random coincidence 
rates were analyzed retrospectively for body position. Because the average injected dose 
of 
18
F -FDG was approximately 340 MBq, the peak NECR attained in underweight 
patients was not apparent in overweight patients. Second, we used the COV for 
quantitative analysis of PET image quality. The COV of the ROI on the liver may vary 
according to PET system, image reconstruction algorithm, and imaging filter. For 
example, the gaussian filter changes image quality by full-width-at-half-maximum 
parameters. This study did not systematically analyze the effect of the gaussian filter on 
PET image quality. However, we elected to use a standard reconstruction algorithm as 
suggested by the vendor. 
 
CONCLUSION 
We have measured the true and random coincidence rates, NECR, and random 
fraction in clinical scanning and evaluated PET image quality. Our findings suggested 
that in 3D LSO 
18
F -FDG PET/CT, the injected dose in underweight patients should be 
reduced 0.8 times, and acquisition time should be approximately 1.4–1.6 times longer in 
overweight patients than in patients of normal weight. Estimation of optimal acquisition 
times by the true coincidence ate based on patient weight is more important than other 
variables in improving PET image quality, especially in overweight patients. 
 
REFERENCES 
1.  Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 
18
F -FDG PET in oncology. J Nucl Med. 2008;49:480–508. 
2.  Halpern BS, Dahlbom M, Quon A, et al. Impact of patient weight and emission 
scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 
2004;45:797–801. 
3.  Halpern BS, Dahlbom M, Auerbach MA, et al. Optimizing imaging protocols for 
overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl 
Med. 2005;46:603–607. 
4.  Everaert H, Vanhove C, Lahoutte T, et al. Optimal dose of 
18
F -FDG required for 
whole-body PET using an LSO PET camera. Eur J Nucl Med Mol Imaging. 
2003;30:1615–1619. 
5.  Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor 
imaging with 
18
F -FDG PET/CT 1.0. J Nucl Med. 2006;47:885–895. 
6.  Zanzonico P. Positron emission tomography. a review of basic principles, scanner  
design and performance, and current systems. Semin Nucl  Med.2004;34:87–111. 
7.  Townsend DW. Positron emission tomography/computed tomography. Semin Nucl 
Med. 2008;38:152–166. 
8.  Watson CC, Casey ME, Bendriem B, et al. Optimizing injected dose in clinical 
PET by accurately modeling the counting-rate response functions specific to 
individual patient scans. J Nucl Med. 2005;46:1825–1834. 
9.  Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E. 
Performance characteristics obtained for a new 3-dimensional lutetium oxy- 
orthosilicate–based whole-body PET/CT scanner with the national electrical 
manufacturers association NU 2-2001 standard. J Nucl Med. 2005;46:2083– 
2091. 
10.  Masuda Y, Kondo C, Matsuo Y, Uetani M, Kusakabe K. Comparison of imaging 
protocols for 
18
F -FDG PET/CT in overweight patients: optimizing scan duration 
versus administered dose. J Nucl Med. 2009;50:844–848. 
11.  Tatsumi M, Clark PA, Nakamoto Y, Wahl RL. Impact of body habitus on quan- 
titative and qualitative image quality in whole-body FDG-PET. Eur J Nucl Med 
Mol Imaging. 2003;30:40–45. 
